SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is facing high volatility as investors speculate on the timing of the 80th clinical event, with the community actively debating whether the current price pullback is a healthy consolidation driven by warrant exercises and profit-taking or a sign of deeper fundamental issues. Long-term bulls remain focused on the upcoming REGAL Phase 3 data, while vocal dissenters continue to challenge the company's clinical history and transparency.

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the market reacts to strong quarterly financial results, including an earnings beat and bullish delivery guidance, which have fueled ongoing community debate over potential stock manipulation. Investors remain sharply divided between those viewing the current share price as a deep-value accumulation opportunity and those frustrated by persistent price volatility despite the company's improving fundamentals.

Applied Digital Corporation

Applied Digital is surging after announcing a significant 15-year hyperscaler lease for its fourth AI campus, fueling community excitement over a growing multibillion-dollar backlog and rising analyst price targets. Shareholders are actively debating the potential for an imminent short squeeze and expressing high conviction in the firm's long-term infrastructure strategy.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is currently a focal point for investors following an influx of federal funding announcements, fueling intense debate over the stock's valuation, dilution risks, and commercial viability versus speculative hype. While bulls emphasize strong growth in bookings and the company's long-term potential in the quantum sector, bears remain skeptical, highlighting significant cash burn and concerns over whether the current momentum is sustainable.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is experiencing extreme volatility as investors digest a combination of robust growth in its AGI CPU pipeline and concerns over supply constraints that capped near-term expectations. The community remains deeply divided, with many traders debating whether current price swings represent a healthy consolidation for a long-term AI infrastructure play or the bursting of a valuation bubble.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit shares are seeing a significant sell-off despite beating earnings and raising guidance, driven by investor anxiety over the potential impact of AI on its tax-software moat and a simultaneous announcement of a 17% workforce reduction. The community is sharply divided between those viewing the decline as a major institutional "smash and grab" overreaction to be bought for long-term value, and skeptics who fear the company's business model is being structurally undermined by emerging AI tools.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing massive momentum and extreme trading volume following news that the company secured a significant letter of intent for government funding to accelerate its neutral-atom quantum technology. The community is actively debating the company's valuation relative to its peers and the long-term strategic validation provided by federal equity stakes.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is generating intense debate as it pivots toward AI data center infrastructure through its new solid-state transformer technology, even as the stock faces downward pressure from ongoing challenges in the residential solar sector. While retail investors remain divided between viewing the move as a major long-term re-rating catalyst and concerns over persistent fundamental headwinds, high short interest has turned the ticker into a volatile battleground for active traders.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing (RGTI) is trending following a massive industry-wide rally triggered by reports of a multi-billion dollar U.S. government investment initiative in quantum technology. The community is sharply divided, with bulls pointing to the long-term strategic validation of the sector, while bears criticize the speculative valuations and high cash burn of these companies.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently trading near historical highs as investors lean into the stock as a defensive "safe haven" amidst broader market volatility and inflationary pressures. While the company faces intense scrutiny over its high valuation multiples, the community remains actively divided between those betting on continued growth through retail dominance and those expecting a significant pullback due to stretched fundamentals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Iran submitted a revised proposal to U.S. negotiators involving sanctions relief and uranium export concessions. However, Trump rejected the proposal over the weekend, calling it “totally unacceptable” on Truth Social.&nbsp;</li><li>Traders are closely watching Tuesday’s inflation print, Trump-Xi talks in Beijing, and geopolitical developments in the Middle East this week.</li><li>AI and memory-chip momentum remained a dominant market theme, with Micron and Everspin among the top-trending stocks on Stocktwits.</li></ul>U.S. stock futures edged lower early Monday as investors weighed the rising crude oil prices amid the latest geopolitical developments in the Middle East. Late Sunday, President Donald Trump rejected Iran’s latest diplomatic peace proposal, calling it “totally unacceptable.”&nbsp;This comes ahead of April CPI inflation data due Tuesday and a closely watched meeting between Trump and Xi Jinping expected later this week in Beijing, their first face-to-face talks in over six months.&nbsp;As of 4:00 a.m. ET on Monday: Nasdaq futures were flat, while S&amp;P 500 and Dow futures declined 0.1%, and Russell 2000 futures edged 0.3% lower.&nbsp;However, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has remained ‘bullish’ since last week.Trending Stocks To WatchMicron (MU), Sandisk Corp (SNDK): Memory-chip stocks continued to dominate retail chatter and trade action as the AI infrastructure trade showed little sign of cooling.&nbsp;Everspin Technologies (MRAM)&nbsp;stock surged 35% in early premarket trade. It has more than doubled since April 29,&nbsp; after posting strong quarterly earnings and highlighting a $40 million U.S. defense subcontract.&nbsp;Biotech stocks are garnering attention. Keep an eye on&nbsp;Moderna (MRNA) and Novavax (NVAX).&nbsp;According to reports, a repatriated American from a luxury cruise ship affected by hantavirus tested mildly positive for the Andes strain, while another individual is exhibiting mild symptoms.MoonLake Immunotherapeutics (MLTX)&nbsp;is trending high on Stocktwits after a positive FDA meeting confirmed a "best-in-class" label strategy for its skin drug.&nbsp;ImmunityBio Inc. (IBRX)&nbsp;remained heavily discussed after last week’s 20% rally, even as shares dipped over 1% in early premarket trade. Investors continued to track founder Patrick Soon-Shiong’s comments on international expansion efforts involving Saudi Arabia and Greece.Alpha Tau Medical (DRTS)&nbsp;stock gained 5% in early premarket trading as investors awaited early U.S. clinical results for its brain cancer radiation therapy, due Monday.&nbsp;Lumentum Holdings Inc (LITE) rose 5% in early trade after Nasdaq announced the company will join the Nasdaq-100 index, replacing CoStar Group Inc., effective May 18.AST SpaceMobile Inc. (ASTS) edged higher ahead of earnings due today.Other tickers trending on Stocktwits at the time of writing included Sun Communities (SUI), Lynas Rare Earths (LYSCF), and Rackspace Technologies (RXT).Other Catalysts To WatchOn earnings radar, watch out for quarterly reports from Circle Internet Group Inc (CIRCL), Fox Corporation (FOXA), monday.com Ltd (MNDY), Constellation Energy Corporation (CEG), and Barrick Mining Corporation (GOLD) today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Dip As Trump-Iran Tensions Lift Crude Oil Prices: Why MU, MRAM, MLTX, DRTS, ASTS Are In Focus

Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ, following last week’s resilience in tech and AI-linked names. 

Equity

Data from Stocktwits shows that retail traders’ sentiment has remained ‘bullish’ on SPY and QQQ, following last week’s resilience in tech and AI-linked names. 


<ul class="summary-bullets"><li>Dow Jones futures, S&amp;P 500 futures, and Nasdaq 100 futures all declined in Sunday’s overnight session.&nbsp;</li><li>Oil prices climbed, with Brent crude futures exceeding $100 a barrel again.</li><li>On the economic front, markets will be watching the U.S. inflation data slated for release on Tuesday.</li></ul>U.S. stock futures slipped in Sunday’s overnight trading session as Washington’s rejection of the peace proposal from Iran weighed on market sentiment, prolonging the possibility of tight global energy supplies and effective closure of the Strait of Hormuz.Dow Jones futures were 0.41% lower at the time of writing, the S&amp;P 500 futures were down 0.25% and Nasdaq 100 futures declined 0.16% as of 8.53 p.m ET. &nbsp;Meanwhile, oil prices climbed higher on the news.Among ETFs tracking benchmark indexes, the <a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, <a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, and the <a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> were all edging lower at the time of writing. Meanwhile, retail sentiment on Stocktwits for SPY and QQQ was in the ‘bullish’ territory, while it was ‘neutral’ for DIA.<h2 class="st-heading-2">How Did US Markets Fare?</h2>On Friday, benchmark indexes closed higher, driven by the April jobs report that came in much stronger than expected, with the S&amp;P 500 and Nasdaq Composite rallying to record highs during the session.The Dow Jones Industrial Average closed 0.03% higher, while the S&amp;P 500 and the Nasdaq Composite climbed 0.84% and 1.71%, respectively.<div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>0.03%</td><td>49,609.16</td></tr><tr><td>S&amp;P 500</td><td>0.84%</td><td>7,398.93</td></tr><tr><td>Nasdaq Composite</td><td>1.71%</td><td>26,247.08</td></tr></tbody></table></figure></div><h2 class="st-heading-2">US Market Drivers</h2>President Donald Trump’s rejection of Iran’s peace proposal sent U.S. stock markets lower over the weekend as markets priced in a longer closure at the Strait of Hormuz that would weigh on global oil prices.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/livecoverage/iran-war-trump-news/card/iran-s-lengthy-response-to-the-u-s-leaves-some-gaps-jVJkux8wKbRUWK9EOOp9">report</a> from the Wall Street Journal, Iran’s “multipage” response to the latest U.S. proposal to end the war included opening the Strait prior to making nuclear concessions, while also agreeing to export some of its highly enriched uranium to a third country, but stopped short of agreeing to dismantle its existing nuclear sites.However, the president called the proposal “TOTALLY UNACCEPTABLE!” in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/116552102914488206">post</a> on Truth Social on Sunday. In an earlier <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/116551553302876569">post</a>, Trump accused Iran of “playing games” with the United States and the rest of the world.Trump is reportedly visiting Beijing on Wednesday and is expected to discuss ‌Iran ⁠, among other topics, with Chinese President Xi Jinping.Markets will also be looking for the U.S. inflation data slated for release on Tuesday, which will provide clues on where key interest rates could be headed.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Micron Technology Inc. (MU): The memory stock surged more than 7% in Sunday’s overnight trading, riding the upward momentum after a red-hot week amid growing demand and a shortage of memory chips. MU stock surged to a record high on Friday and has gained a whopping 709% in the past 12 months.Sandisk Corp. (SNDK): The Milpitas, California-based company’s shares also rallied by over 5% in the overnight session heading into Monday on account of the AI memory supercycle and explosive demand for memory chips.Everspin Technologies Inc. (MRAM): Shares of the company surged more than 48% in extended trading hours, on track for their best day since November 2021. Everspin shares have been bolstered higher by strong first-quarter 2026 earnings and a recent $40 million defense subcontract with the U.S. Department of War.MoonLake Immunotherapeutics (MLTX): The company’s stock <a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-soars-on-fda-backing-clear-street-upside-call/cZX9nINReW3">surged more than 7%</a> in overnight trading after the company said it had conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), in which the apex body aligned on submission plans and the label strategy for its skin drug.<h2 class="st-heading-2">Broader Market Trends</h2>Oil futures climbed higher in Sunday’s overnight session. Brent crude futures expiring in July were up about 3.51%, trading at around $104.85 a barrel, while WTI crude futures expiring in June were 3.89% higher, at $99.13 a barrel at the time of writing.American economist and professor at The Johns Hopkins University, Steve Hanke, warned that oil prices would go higher amid the war. “Once inventories run dry, we will switch from an oil deficit to an oil shortage. Then, prices will SPIKE, AGAIN,” he said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/steve_hanke/status/2053497792627397054">post</a> on X.Meanwhile, treasury yields on the benchmark 10-year were at 4.39%, while gold declined to trade around $4,676.59 an ounce.Asian markets were mixed at the open on Monday, with the KOSPI and Nikkei 225 gaining at the time of writing, while the SSE Composite index was largely flat. Australian stocks were lower at the open.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative Image (Photo credit: Getty Images)

Dow, S&P 500, Nasdaq Futures Slip As Trump Calls Iran’s Peace Proposal ‘Totally Unacceptable’ — MU, SNDK, MRAM, MLTX Stocks In Focus

Iran’s “multipage” response reportedly included opening the Hormuz Strait prior to making nuclear concessions, while also agreeing to export some of its highly enriched uranium to a third country.

<ul class="summary-bullets"><li>MoonLake said that the FDA agreed to include results from both the Phase 2 Mira study and Phase 3 Vela trials in the proposed drug label.</li><li>Clear Street maintained a ‘Buy’ rating and $70 price target on MLTX, implying a 310% upside from current levels.</li><li>MoonLake ended the first quarter with $357.9 million in cash and said its current funding runway extends through the end of 2027.</li></ul>Shares of MoonLake Immunotherapeutics, Inc. (MLTX) jumped 7% in overnight trading heading into Monday after the company said that the U.S. Food and Drug Administration (FDA) aligned on its approval filing plans for Sonelokimab, prompting Clear Street to say that the skin therapy could emerge with a “stronger, best-in-class label.”<a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> snapped two straight weeks of weekly losses and ended 2% higher last week at $17.06.<h2 class="st-heading-2">FDA Backs MoonLake HS Drug Filing</h2>On Sunday, MoonLake said that its final pre-biologics license application (BLA) meeting with the FDA concluded with alignment on certain parts of its application for Sonelokimab in hidradenitis suppurativa (HS), a chronic inflammatory skin disease.MoonLake said that the FDA agreed the results from both its mid-stage Mira study and late-stage Vela trials can be included in the proposed prescribing label for Sonelokimab, boosting the drug’s case for approval in HS. The company also said that the FDA supported including data from the Vela-Teen study, which could allow the treatment to be approved for patients aged 12 and older.&nbsp;The company plans to apply for a Priority Review designation and expects to submit the BLA application by September. Acceptance of the filing, including a decision on Priority Review status, is expected by November. MoonLake also said that the FDA identified no remaining gaps, including manufacturing-related issues, that would prevent the filing.MoonLake said that the proposed label could highlight that 43% of patients in the Mira study achieved a high level of symptom improvement after 12 weeks of treatment, with results outperforming placebo by 29 percentage points. According to the company, the efficacy levels are the strongest reported so far in any well-controlled late-stage clinical study for HS.&nbsp;<h2 class="st-heading-2">Clear Street Sees ‘Best-In-Class’ Label</h2>After the FDA meeting, Clear Street said that MoonLake’s positive pre-application meeting restores the company to its “prior strong positioning” in the HS market. The brokerage said that the FDA’s agreement to include both Mira efficacy data and Vela trial results in the label could result in a “stronger, best-in-class label” for Sonelokimab.Clear Street maintained a ‘Buy’ rating on the stock with a $70 price target, implying&nbsp; an upside of 310% from current levels.&nbsp;<h2 class="st-heading-2">MLTX Cash Runway Extends Into 2027</h2>As of March 31, MoonLake held $357.9 million in cash, cash equivalents and short-term marketable securities,&nbsp;which it expects to fund operations and spending through the end of 2027.The company also retains access to up to $400 million in additional non-dilutive funding through its Hercules Capital debt facility. Research and development expenses totaled $54.5 million during the first quarter, compared with $56 million in the previous quarter. General and administrative expenses rose to $15.5 million from $9.2 million in the prior quarter. MoonLake said the increase was mainly from $4.8 million in accelerated expense recognition related to the voluntary cancellation of unvested stock option awards.<h2 class="st-heading-2">MLTX Reports Strong Long-Term HS Results</h2>The FDA update comes on the heels of encouraging long-term clinical data reported by MoonLake from the Phase 3 Vela-1 and Vela-2 trials in HS. In March, the company said 62% of patients treated with Sonelokimab achieved strong clinical improvement after 40 weeks, while up to 32% saw their skin lesions become nearly clear.Up to 25% of patients achieved inflammatory remission, meaning that the key signs of the disease disappeared completely. Patients also reported improvements in pain, mobility and daily activities such as walking and dressing. According to the company, up to 43% of patients saw reductions in their worst skin pain, while 65% reported improvements in overall quality of life.&nbsp;<h2 class="st-heading-2">More Trial Catalysts Ahead For MLTX</h2>Earlier this year, MoonLake reported positive mid-stage trial results for Sonelokimab in axial spondyloarthritis, an inflammatory condition that affects the spine and joints. The company said that 81% of patients showed improvement within 12 weeks of treatment, with scans and disease markers also indicating reduced inflammation and disease activity.&nbsp;Investors are now watching several upcoming catalysts over the next year, including 52-week data from the Phase 3 Vela studies in the second quarter, results from the Phase 3 Izar-1 trial in psoriatic arthritis and data from the Vela-Teen adolescent study in mid-2026, followed by the BLA submission for HS by the end of September.<h2 class="st-heading-2">How Do Retail Traders Feel About MLTX?</h2>On Stocktwits, retail sentiment for MLTX flipped to ‘bullish’ from ‘bearish’ levels a day ago amid nearly a 400% surge in 24-hour message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/mltx_ss_png_c58df845f7.webp" alt="mltx ss.png" width="969" height="143"><figcaption>MLTX sentiment and message volume as of May 10 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/WallStWolf38/message/652889422">said</a>, “Looking forward to tomorrow! We’ve already been through a lot with this stock. But with this news, the selling pressure should be very low, and it should be possible to break through the USD 20 . After that, it’ll be easier to move higher.”<stembedurl>https://stocktwits.com/WallStWolf38/message/652889422</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Creisi/message/652878950">said</a>, “There's literally nothing standing in SLK's path to becoming Best in Class across all Inflammatory skin disease indications. Furthermore, we have zero concern of dilution which almost always happens during phase 3 trials nearing drug BLA submission.”<stembedurl>https://stocktwits.com/Creisi/message/652878950</stembedurl>MLTX stock has declined 57% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-flips-tesla-again-in-trillion-dollar-tug-of-war/cZX72SBReWP">Bitcoin Flips Tesla Again In Trillion-Dollar Tug-Of-War&nbsp;</a>

In this photo illustration, a MoonLake Immunotherapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

MLTX Stock Soars Overnight After FDA Backs Skin Drug Filing — Analyst Sees Over 300% Upside On ‘Best-In-Class’ Label

Shares of MoonLake Immunotherapeutics, Inc. (MLTX) jumped 7% in overnight trading heading into Monday after the company said that the U.S. Food and Drug Administration (FDA) aligned on its approval filing plans 

The company plans to submit its biologics license application (BLA) by September.


MoonLake Immunotherapeutics (MLTX) to Release Earnings on Monday

MoonLake Immunotherapeutics (NASDAQ:MLTX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-moonlake-immunotherapeutics-stock...

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) has been given an average rating of "Hold" by the sixteen brokerages that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, four have issued a hold r...

Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2%

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) saw a large decrease in short interest in April. As of April 15th, there was short interest totaling 6,654,522 shares, a decrease of 14.2% from the March 31st total of 7,757,169 shares. Based on an average daily trading volume, of...

The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?

Key PointsCEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share...

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Sells $945,644.79 in Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of the company's stock in a transaction dated Monday, April 13th. The shares were sold at an...

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 98,127 Shares

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of...

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 51,873 Shares

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 51,873 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Monday, April 13th. The...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MLTX
MoonLake Immunotherapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest MLTX News

MLTXMoonLake Immunotherapeutics